Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Share-based Compensation for 10 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 88.51% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Dec 2025, up 45.12% year-over-year, with the annual reading at $11.3 million for FY2025, 45.12% up from the prior year.
  • Share-based Compensation for Q4 2025 was $3.2 million at Akebia Therapeutics, down from $3.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $6.9 million in Q2 2022, with the low at $1.5 million in Q4 2023.
  • Average Share-based Compensation over 5 years is $3.4 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Share-based Compensation crashed 50.21% in 2023, then skyrocketed 95.69% in 2025.
  • Over 5 years, Share-based Compensation stood at $4.6 million in 2021, then crashed by 34.4% to $3.0 million in 2022, then plummeted by 50.21% to $1.5 million in 2023, then grew by 12.09% to $1.7 million in 2024, then soared by 88.51% to $3.2 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $3.2 million, $3.2 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.